TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 26, 2020
March 19 2020 - 9:00AM
Business Wire
Company to hold conference call and webcast at
8:30 AM EDT
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative drug products based on its patented Thin Film Freezing
(TFF) technology platform, today announced that it will release its
financial results for fourth quarter and full-year 2019 and
business update on Thursday, March 26, 2020. The Company's
management will host a conference call to discuss the financial
results and provide a business update on recent corporate and
clinical developments at 8:30 a.m. Eastern Time.
Conference Call Details:
Thursday, March 26, 2020, 8:30 a.m. Eastern Time (ET)
Domestic Dial-In Number: Toll-Free: (800)
816-3024
International Dial-In Number (857)
770-0106
Conference ID: 7695599
Webcast URL:
https://edge.media-server.com/mmc/p/k9qym597
The conference call will also be broadcast live and available
for replay for one month on the Company's website,
https://tffpharma.com, in the Events Calendar of the Investors
section. Please access the Company's website at least 15 minutes
ahead of the conference to register, download, and install any
necessary audio software.
About TFF Pharmaceuticals’ Thin Film Freezing technology
platform
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was
designed to improve the solubility and absorption of poorly
water-soluble drugs and is particularly suited to generate dry
powder particles with properties targeted for inhalation delivery,
especially to the deep lung, an area of extreme interest in
respiratory medicine. The TFF process results in a “Brittle Matrix
Particle,” which possesses low bulk density, high surface area, and
typically an amorphous morphology, allowing the particles to
supersaturate when contacting the target site, such as lung tissue.
Based upon laboratory experiments, the aerodynamic properties of
the particles are such that the portion of a drug deposited to the
deep lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative drug
products based on its patented Thin Film Freezing, or TFF,
technology platform. Early testing confirms that the TFF platform
can significantly improve the solubility and absorption of poorly
water-soluble drugs, a class of drugs that comprises approximately
one-third of the major pharmaceuticals worldwide, thereby improving
their pharmacokinetics. TFF Pharmaceuticals has two lead drug
candidates: Voriconazole Inhalation Powder and Tacrolimus
Inhalation Powder. The Company plans to add to this pipeline by
collaborating with large pharmaceutical partners. The TFF Platform
is protected by 39 patents issued or pending in the US and
internationally. To learn more about TFF Pharmaceuticals and its
product candidates, visit the Company’s website at
https://tffpharma.com.
###
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200319005404/en/
Company Contacts: Glenn Mattes President and CEO TFF
Pharmaceuticals, Inc. gmattes@tffpharma.com 737-802-1973
Kirk Coleman Chief Financial Officer TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com 817-989-6358
Investor Relations and Media Contact: Paul Sagan
LaVoieHealthScience psagan@lavoiehealthscience.com 617-953-4779
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Mar 2024 to Apr 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Apr 2023 to Apr 2024